Brief: Bellicum Announces Update On Clinical Hold Of U.S. BPX-501 Studies
23/02/2018 12:00
Feb 23 (Reuters) - Bellicum Pharmaceuticals Inc BLCM.O :
* BELLICUM ANNOUNCES UPDATE ON CLINICAL HOLD OF U.S. BPX-501
STUDIES
* BELLICUM - RECEIVED NOTIFICATION FROM FDA OUTLINING
CRITERIA
REQUIRED FOR LIFTING CLINICAL HOLD ON U.S. STUDIES OF BPX-501
* BELLICUM PHARMACEUTICALS INC - CLINICAL HOLD DOES NOT
AFFECT
COMPANY'S BP-004 REGISTRATION TRIAL IN EUROPE
* BELLICUM - PLANS TO IMPLEMENT REVISIONS TO U.S. STUDY
PROTOCOLS,
ADDITION OF MORE COMPREHENSIVE MONITORING, MANAGEMENT OF
NEUROTOXICITY FOR BPX-501
Source text for Eikon: ID:nGNX85SfNJ
Further company coverage: BLCM.O
((Bangalore.newsroom@thomsonreuters.com; ;))
Recent news on Bellicum Pharmaceuticals
See all newsBrief: Bellicum Pharmaceuticals- In Connection With Dissolution And Plan Of Dissolution, On February 23, Richard A. Fair Resigned As President And Co's CEO
Brief: Bellicum Pharmaceuticals Says Board Approved Liquidation And Dissolution Of Co In Connection With Approval Of Asset Purchase Agreement
Brief: Bellicum Pharmaceuticals Initiated A 12 Stock Split On Dec 8, 2022
Brief: Bellicum Reports Third Quarter 2022 Financial Results And Provides Operational Update
Bellicum Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview